Stromasys: Double Virtualisation: CHARON and VMware Deliver Maximum Reliability for Legacy Systems
VMware confirms: Stromasys virtual servers are “VMware READY”. IT administrators are now able to enjoy maximum reliability for legacy DEC systems.
Today, Stromasys S.A. is pleased to announce that its CHARON line of cross platform virtualisation products has received the VMware Ready logo. The software virtualises Digital Equipment Corporation (DEC) PDP-11, VAX systems, and AlphaServers. VMware has now confirmed that Charon virtual servers are supported on virtual machines in the VMware ESXi environment. This “double virtualisation” offers IT administrators almost complete failure protection for their legacy systems. “With this announcement and future enhancement planned for CHARON on VMware, customers can now have a unified and standard data center infrastructure for both their main stream applications and legacy systems, a unique value proposition brought together by Stromasys and VMware“, said Robert Boers, Chairman and CEO of Stromasys.
Once the IT administrator has installed CHARON on a virtual Windows or Linux system in VMware, the virtual system can be managed with vSphere like any other virtual machine. Should there be hardware problems, even an active application together with its virtual server system can be moved to a backup VMware server using vMotion. “By using virtual servers on VMware we were able to almost completely eliminate the risk of an outage, while our application continue to run on VMS”, explains Janos Kreis, System Manager at Kraus & Naimer. Kraus & Naimer has been using CHARON for various VAX server models in conjunction with VMware for several months.
For some time now, many IT administrators have been waiting for CHARON to receive the VMware Ready logo, because large companies and government organisations are still working with OpenVMS on DEC VAX and AlphaServer systems, which were built in the 1980s and 1990s. The operating system still has the reputation to be the safest and most stable of its kind, but frequently hardware threatens to fail after more than 20 years of productive use. Together, CHARON and VMware will ensure that operating system and applications can continue to be used without any interruption.
About Stromasys
Stromasys S.A. is a privately held, global
company headquartered in Geneva, Switzerland which provides commercial
cross-virtualization technologies to thousands of users. Stromasys has
now sold more than 4000 virtual servers in over 50 countries.
Established in 1998, Stromasys was formed from a management buyout of
Digital Equipment Corporation’s European Migration and Porting centre
following the HP/Compaq merger. The vast experience gained from years of
large-scale migration and porting projects, system-level VMS engineering
projects, and development of binary translators led to the creation of
CHARON-VAX and CHARON-AXP software products. With full service sales and
support locations in the United States, Germany, and Hong Kong,
engineering facilities in Russia and China, and worldwide
representation, Stromasys continues to expand, bringing additional
cross-virtualization technologies for legacy platforms to the market. www.stromasys.com
.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6684131&lang=en
Contact:
Kate Godden
E-mail: kate.godden@stromasys.com
Tel:
+41-22-794 1070
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom